NS
INDV icon

NBC Securities’s Indivior Pharmaceuticals INDV Stock Holding History

NBC Securities’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-470
Closed -$4K – 1654
2024
Q3 		$4K Hold
470
– – ﹤0.01% 1931
2024
Q2 		$7K Hold
470
– – ﹤0.01% 1774
2024
Q1 		$11K Hold
470
– – ﹤0.01% 1677
2023
Q4 		$7K Hold
470
– – ﹤0.01% 1800
2023
Q3 		$10K Buy
+470
New +$10.7K ﹤0.01% 1702

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

NBC Securities's INDV Position: Q4 2024 in Review

NBC Securities sold out of Indivior Pharmaceuticals (INDV) in Q4 2024, closing a stake of 470 shares — an estimated $4K sold.

NBC Securities first reported a position in INDV in Q3 2023 and held it in 5 quarters. The position peaked at $11K in Q1 2024. 113 funds tracked by Wall St. Rank hold INDV as of Q4 2024.

  • NBC Securities reported no remaining Indivior Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • NBC Securities sold 470 Indivior Pharmaceuticals shares in Q4 2024, an estimated $4K.
  • NBC Securities first reported a position in Indivior Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • NBC Securities's Indivior Pharmaceuticals position peaked at $11K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2024.

Based on NBC Securities's 13F filing for Q4 2024, filed 22 Jan 2025.